cv-1

S-23 ((S)-3-(4-chloro-3-fluorophenoxy)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide) is an oral selective androgen receptor modulator (SARM) with a Ki of 1.7 nM. S-23 increases prostate, seminal vesicle, and levator ani muscle weights in castrated rats.

CV-159 is a distinctive dihydropyridine Ca2+ antagonist exhibiting anti-inflammatory properties and possessing anti-calmodulin (CaM) activity.

CV-1674 induced selective coronary vasodilation and had little effect on cardiac hemodynamics.

HCV-1 e2 Protein (554-569), a primary antigenic region within the Hepatitis C Virus envelope 2 (e2) protein, contains a putative N-glycosylation site believed to affect immune recognition of e2 [1].

HCV-1 e2 Protein (484-499) is a 16-amino acid peptide derived from the envelope 2 protein of the hepatitis C virus, identified in the sera of individuals possessing antibodies to HCV [1].

HCV-1 e2 Protein (554-569) TFA, an antigenic segment of the hepatitis C virus envelope 2 (e2) protein, contains a potential N-glycosylation site that may influence immune recognition of e2 [1].

Chloroquinoxaline sulfonamide (Chloroquinoxaline) is a topoisomerase II alpha/beta toxin with antitumor activity and immunosuppressive properties that inhibits the proliferation of B16 melanoma cells in mice, and can be used to study metastatic colorectal cancer. It can be used to study metastatic colorectal cancer.

Furaprofen is an orally available, selective and potent HCV inhibitor with anti-inflammatory activity, inhibits carrageenan-induced paw edema in rats and inhibits cotton pellet-induced granulomas in rats at higher doses.

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antivirals to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has not been convincingly implicated in cases of clinically apparent liver injury with jaundice.

Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist (IC50: 0.26 nM). Upon hydrolysis to candesartan during gastrointestinal absorption, it selectively competes with angiotensin II for binding to the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation.

Candesartan-D4 is the deuterated form of Candesartan (TMSM-3481). It is an orally active Angiotensin II AT1 receptor blocker and PPAR-γ agonist with long-lasting antihypertensive effects, used as an internal standard in PK studies.

Candesartan (CV 11974) is an angiotensin II receptor blocker widely used in the treatment of hypertension and heart failure.

Inarigivir soproxil (SB9200) is an agonist of innate immunity that demonstrates effective antiviral activity against resistant hepatitis C virus (HCV) variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.

JTK-853 is a novel, non-nucleoside inhibitor of Hepatitis C Virus (HCV) polymerase, exhibiting effective antiviral activity in HCV replicon cells with EC50s of 0.38 μM for genotype 1a H77 strain and 0.035 μM for genotype 1b Con1 strain.

NITD008 (7-Deaza-2'-C-acetylene-adenosine) is a potent and selective adenosine nucleoside inhibitor.NITD008 is an adenosine nucleoside analog with broad-spectrum antiviral activity that inhibits dengue, animal cupripoxvirus, and Zika virus.

CV-1808 is a coronary vasodilator, antihypertensive, and antipsychotic following systemic administration in vivo. CV-1808 is an adenosine A2 receptor agonist.

Usp39 PROTAC-V1 is a highly efficient PROTAC degrader targeting the splicing protein USP39, which primarily degrades intracellular USP39 via selective proteasomal degradation.

Paritaprevir free base (ABT-450) is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells.

CV 11464 is a bioactive chemical.

Asunaprevir (BMS-650032) is an effective hepatitis C virus (HCV) NS3 protease inhibitor.

CV122 is a potent inhibitor of heparanase (heparanase), exhibiting an IC50 of 2.97 µM. This compound inhibits pro-inflammatory cytokines and can be utilized in sepsis research.

Neuronal nicotinic receptor antagonist

Chlamydia pneumoniae-IN-1 (compound 55), a benzimidazole derivative, exhibits potent antibacterial activity, inhibiting 99% of C. pneumoniae growth at a concentration of 10 μM while maintaining 95% viability of host cells. It effectively inhibits the CV-6 strain of C. pneumoniae with a minimum inhibitory concentration (MIC) of 12.6 μM, demonstrating its antichlamydial efficacy [1].

Rupatadine (UR-12592, rupatadine) is a potent and orally available dual antagonist of PAF and histamine H1 receptors with Ki values of 0.55 μM and 0.1 μM, respectively, which provides relief of allergic symptoms and anti-inflammatory properties, and is used in allergic rhinitis and chronic urticaria.